ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2331

Next Generation Sequencing Analysis of Familial Haemophagocytic Lymphohistiocytosis (HLH) Related Genes in Macrophage Activation Syndrome (MAS) and Secondary HLH (sHLH)

Chiara Passarelli1, Manuela Pardeo2, Ivan Caiello3, Elisa Pisaneschi1, Antonio Novelli1, Fabrizio De Benedetti4 and Claudia Bracaglia2, 1Unit of Medical Genetics, Laboratory of Cytogenetics and Molecular Genetics, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 2Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, 3Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, 4Division of Rheumatology, IRCCS Bambino Gesù Children's Hospital, Rome, Rome, Italy

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: genetics and macrophage activation syndrome, Systemic JIA

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Pediatric Rheumatology – Pathogenesis and Genetics Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Macrophage activation syndrome (MAS) is a severe complication of rheumatic disease, particularly of systemic JIA (sJIA). It is currently classified among the secondary forms of HLH (sHLH). Primary HLH (pHLH) is caused by mutation of genes that code for proteins that are involved in cytotoxic functions. Mice carrying heterozygous mutations in more than 1 pHLH gene carry a higher risk to develop HLH following viral infection, suggesting that accumulation of partial genetic defects may be relevant in HLH.

Methods: Genes involved in pHLH were analysed, with next generation sequencing (NGS), in MAS in the context of different rheumatic diseases and in sHLH. A Targeted resequencing were performed on all patients using a panel including the 7 principal HLH-related genes (PRF1, UNC13d, STX11, STXBP2, RAB27a, XIAP, SH2D1A). Sequencing analysis were performed on the MiSeq® and NextSeq550® platforms (Illumina, San Diego, CA); all variants identified were confirmed by Sanger. The possible functional impact of variants was studied by in silico analysis using SIFT and PolyPhen softwares. We took into account only variants with anallelic frequency in the global population up to 1%, in the dbSNP and Ensembl databases, with the exception of A91V variant in PRF1 gene, because of its conflicting interpretation of pathogenicity.

Results: Fifty patients, 29 MAS (23 developed this complication in the context of sJIA, and 6 developed MAS respectively in the context of systemic vasculitis, Crohn’s disease, systemic lupus erythematosus, anti-phospholipid syndrome, chronic recurrent multifocal osteomyelitis and Kawasaki disease) and 21 patients with HLH secondary to infections or without any demonstrable trigger, were analysed. At least 1 heterozygous variant was identified in one of the pHLH-associated genes in 24 patients (12/29 MAS, 12/21 sHLH) with a detection rate of 48%. Seventeen patients (34%) showed only 1 variant, while more than 1 variant were found in 7 patients (14%). Seven (24%) patients with MAS showed the A91V variant in PRF1 in an heterozygous state, and 5 (17%) patients showed an heterozygous variant in UNC13d gene. Four of the 29 MAS patients had mutations in two different genes: one of them had recurrent episodes of MAS with a severe disease and a prolonged ICU admission. Two MAS patients carried 2 heterozygous variants in the same gene. Three (14%) patients with sHLH showed a heterozygous mutation in RAB27a, 3 in UNC13d and 4 in PRF1 gene. Two patients carried more than a single heterozygous variant: one had variants in two different genes, while one patient showed 3 different variants in the same gene (PRF1). For two of these patients with variants in two different genes, one of them presented three episodes of HLH reactivation and the other one presented a severe disease with exitus.

Conclusion: Mutations of PRF1 and UNC13d genes were frequently observed in patients with MAS or secondary HLH; RAB27a variants seems to be more frequent in patients with sHLH. Re-occurrence and severity of disease tend to be more frequent and more severe in sHLH patients who carry mutations in two genes. The contribution of these variants to the risk of MAS or sHLH remains to be established in the context of a polygenic model of sHLH and MAS.


Disclosure: C. Passarelli, None; M. Pardeo, None; I. Caiello, None; E. Pisaneschi, None; A. Novelli, None; F. De Benedetti, Novartis, Roche, Pfizer, SOBI, AbbVie, Novimmune, BMS, Sanofi, 2; C. Bracaglia, None.

To cite this abstract in AMA style:

Passarelli C, Pardeo M, Caiello I, Pisaneschi E, Novelli A, De Benedetti F, Bracaglia C. Next Generation Sequencing Analysis of Familial Haemophagocytic Lymphohistiocytosis (HLH) Related Genes in Macrophage Activation Syndrome (MAS) and Secondary HLH (sHLH) [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/next-generation-sequencing-analysis-of-familial-haemophagocytic-lymphohistiocytosis-hlh-related-genes-in-macrophage-activation-syndrome-mas-and-secondary-hlh-shlh/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/next-generation-sequencing-analysis-of-familial-haemophagocytic-lymphohistiocytosis-hlh-related-genes-in-macrophage-activation-syndrome-mas-and-secondary-hlh-shlh/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology